Emily Walsh Martin, PhD, spoke with Amber Freed, founder and CEO of SLC6A1 Connect, a patient organization focused on accelerating the development of therapies for SLC6A1 patients like her son Maxwell.

Using AI to Drive Innovation in CGT with Le Cong, PhD
48:29

The biological clock of aging and the possibility of lifespan extension with Christin Glorioso and John Bell
39:13

Against the Odds: How Dr. Anna Maurer Built a Life in Science
33:17